ZEPATIER

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug ZEPATIER contains a combination of these active pharmaceutical ingredients (APIs):

1	Elbasvir UNII 632L571YDK - ELBASVIR
	Read more about Elbasvir
2	Grazoprevir UNII 8YE81R1X1J - GRAZOPREVIR ANHYDROUS
	Read more about Grazoprevir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZEPATIER Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AP54		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections
Discover more medicines within J05AP54

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	525518010020302
CA	Health Products and Food Branch	02451131
EE	Ravimiamet	1725870
ES	Centro de información online de medicamentos de la AEMPS	1161119001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	050068
FR	Base de données publique des médicaments	66198173
GB	Medicines & Healthcare Products Regulatory Agency	334084, 369093
HK	Department of Health Drug Office	65571, 66768
IL	מִשְׂרַד הַבְּרִיאוּת	7989
IT	Agenzia del Farmaco	044929014
LT	Valstybinė vaistų kontrolės tarnyba	1080792
NL	Z-Index G-Standaard, PRK	137545
PL	Rejestru Produktów Leczniczych	100376883
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64591001
SG	Health Sciences Authority	15404P
US	FDA, National Drug Code	0006-3074